文献速递妇科

复发性宫颈癌HER2状态动态变化:强调再评估的临床价值

Dynamics of HER2 status in recurrent cervical cancer: Highlighting the clinical value of reassessment.
PubMed 文献 · Gynecol Oncol · 2026-08-11

该单中心回顾性研究纳入2013至2024年118例复发性宫颈癌患者,对复发灶及配对原发灶行HER2免疫组化并按2017 ASCO/CAP胃食管腺癌指南评分。复发灶HER2阳性率为15.3%,腺癌和既往放疗野外复发与阳性独立相关;72对配对样本中7例(9.7%)存在HER2不一致,腺癌是唯一相关因素。

要点

  • 复发性宫颈癌HER2阳性率为15.3%,腺癌高于鳞癌(30.6% vs 8.6%)。
  • 腺癌和既往放疗野外复发是HER2阳性的独立相关因素。
  • 配对原发与复发灶HER2不一致率9.7%,腺癌与不一致相关。

核心结论

  • 复发性宫颈癌中HER2阳性与宫颈内膜腺癌及既往放疗野外复发相关。
  • 复发时再活检重新评估HER2可能为部分患者的治疗选择提供依据。

研究设计与样本

  • 单中心回顾性研究,纳入2013至2024年治疗的复发性宫颈癌患者118例。
  • 对复发灶及配对原发灶行HER2免疫组化,按2017 ASCO/CAP胃食管腺癌指南评分,2+或3+判为阳性。
  • 采用logistic回归分析与HER2阳性相关的因素。

主要发现

  • 复发灶HER2阳性率为15.3%(18/118)。
  • 宫颈内膜腺癌HER2阳性率高于鳞状细胞癌(30.6% vs 8.6%,P = 0.009)。
  • 腺癌与HER2阳性独立相关(调整OR 4.80;95%CI 1.60-15.66)。
  • 既往放疗野外复发与HER2阳性独立相关(调整OR 7.92;95%CI 1.68-77.86)。
  • 72对配对样本中7例(9.7%)HER2不一致,包括61例中4例(6.6%)HER2获得和11例中3例(27.3%)HER2缺失。

关键数值与推荐

  • HER2免疫组化按2017 ASCO/CAP胃食管腺癌指南评分,2+或3+为HER2阳性。
  • 腺癌是不一致唯一相关因素(OR 10.33;95%CI 1.99-104.04)。

临床怎么用

  • 对复发性宫颈癌,尤其腺癌或既往放疗野外复发者,可考虑复发灶再活检评估HER2。
  • 原发灶HER2结果不能完全代表复发灶状态,治疗决策前应结合复发灶再评估。

局限性

  • 单中心回顾性研究,样本量有限。
  • 配对样本仅72对,不一致分析效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates have emerged as a promising therapy, making accurate HER2 assessment important. We assessed HER2 expression in recurrent cervical cancer, examined clinicopathological factors associated with HER2 positivity at recurrence, and analyzed HER2 discordance between matched primary and recurrent tumors. METHODS: We retrospectively identified patients with recurrent cervical cancer treated at a single center between 2013 and 2024. HER2 immunohistochemistry was performed on recurrent and matched primary tumors and scored according to the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma. Tumors scoring 2+ or 3+ were classified as HER2-positive. Factors associated with HER2 positivity were analyzed by logistic regression. RESULTS: Among 118 patients, the HER2-positive rate in recurrent tumors was 15.3% (18/118). HER2 positivity was higher in endocervical adenocarcinoma than in squamous cell carcinoma (30.6% vs 8.6%, P = 0.009). Adenocarcinoma (adjusted odds ratio [OR] 4.80; 95% confidence interval [CI], 1.60-15.66) and recurrence outside the prior radiotherapy field (adjusted OR 7.92; 95% CI, 1.68-77.86) were independently associated with HER2 positivity. Among the 72 matched pairs, HER2 discordance was observed in 7 (9.7%), including HER2 gain in 4 of 61 (6.6%) and HER2 loss in 3 of 11 (27.3%). Adenocarcinoma was the only factor associated with discordance (OR 10.33; 95% CI, 1.99-104.04). CONCLUSIONS: In recurrent cervical cancer, HER2 positivity was associated with endocervical adenocarcinoma and recurrence outside the prior radiotherapy field. Reassessing HER2 by re-biopsy at relapse may inform treatment selection in a subset of patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Seo JH, Lee Y, Lim S, et al. Dynamics of HER2 status in recurrent cervical cancer: Highlighting the clinical value of reassessment. Gynecol Oncol. 2026. PMID: 42579944. doi:10.1016/j.ygyno.2026.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。